title: Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.
abstract: OBJECTIVE
  We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas.
  
  
  METHODS
  Fifteen adult patients were treated; 14 were treated with 300 mg/m(2) and one treated with 250 mg/m(2).
  
  
  RESULTS
  We reviewed the toxicity, progression-free survival (PFS), overall survival and objective response rate. Two patients (13%) experienced grade 3 nausea/vomiting and six patients (40%) experienced grade 3 lymphopenia. Dose reduction and treatment delay occurred in eight (53%) cases. One patient discontinued treatment due to uncontrolled nausea/vomiting. Median PFS for glioblastoma patients was 4.1 months and 6-month PFS was 25%. Twelve patients exhibited stable disease (86%), one patient (7%) had progressive disease and one patient (7%) showed a partial response.
  
  
  CONCLUSIONS
  The '3 on/11 off' temozolomide regimen for recurrent high-grade gliomas was tolerable and warrants further study in a larger, prospective study.
authors.affiliation: Center for Translational Neuro-Oncology, Department of Neurosciences, Moores Cancer Center, UC San Diego, La Jolla, CA, USA.
authors.forename: Vincent A
authors.initials: VA
authors.lastname: van Vugt
authors.forename: David E
authors.initials: DE
authors.lastname: Piccioni
authors.forename: Bradley D
authors.initials: BD
authors.lastname: Brown
authors.forename: Tiffany
authors.initials: T
authors.lastname: Brown
authors.forename: Marlon G
authors.initials: MG
authors.lastname: Saria
authors.forename: Tiffany
authors.initials: T
authors.lastname: Juarez
authors.forename: Santosh
authors.initials: S
authors.lastname: Kesari
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D017567:Karnofsky Performance Status; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D000077204:Temozolomide; D013997:Time Factors
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide
keywords: alternative regimens; chemotherapy; glioblastoma; glioma temodar; safety; temozolomide